MIcrovascular Dysfunction in CRitically Ill cOVID-19 Patients (MICROVID)

Microvascular Flow Alteration and Endothelial Dysfunction in Critically Ill Patient With Covid-19

Microcirculatory dysfunction appears to play a key role in the development of organ failure leading to the death of patients with coronavirus disease 2019 (Covid-19). It is still uncertain today whether this damage is secondary to direct viral infection of endothelial cells or the consequence of the inappropriate inflammatory response induced by the infection. The analysis of endothelial and microcirculatory dysfunctions and glycocalyx degradation therefore appears to be necessary in the understanding of the pathophysiological mechanisms of Covid sepsis and could play a role in the evaluation of the efficacy of certain therapeutics which would aim at improving regional perfusion by decreasing microcirculatory dysfunction.However, the analysis of microcirculatory failure, endothelial dysfunction and glycocalyx degradation has so far only been evaluated in small cohorts, without quantitative analysis of microcirculatory perfusion

Study Overview

• Status: Unknown
• Conditions: Covid-19; Critical Illness; SARS-CoV Infection; Hemodynamics
• Intervention / Treatment: Other: Measurement of sublingual microcirculation; Other: Plasma sampling

Detailed Description

The study of pathophysiological mechanisms of cellular penetration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) allows the understanding of organ failures observed in COVID 19. In order to allow its fusion with the cell membrane, SARS-Cov-2 must bind the Angiotensin Converting Enzyme 2 (ACE2) via its Spike protein. This process requires the priming of the viral S protein by a cellular serine protease TMPRSS2. Thus, any cell co-expressing these two receptors is a potential target for the virus. Among all the cells for which this co-expression could be observed, endothelial cells and vascular pericytes seem to be potential targets, whose infection could lead to the development of an endothelial dysfunction responsible for microcirculatory dysfunction. In addition, inappropriate host immune system response observed in Covid-19 with massive production of pro-inflammatory cytokines as IL-6, TNF α and VEGF could lead to endothelial dysfunction through neutrophils, monocytes and macrophages mobilization producing Reactive Oxygen Species that increase endothelium and glycocalyx damages. The resulting pro-adhesive, pro-vasoconstricting and prothrombotic effects could lead to vascular micro-thrombosis, capillary plugging and impairment of capillary flow.

Whether endothelial dysfunction is caused by direct viral cell infection or pro-inflammatory response is uncertain, but various studies have confirmed that endotheliopathy plays a key role in pathophysiological mechanisms in Covid 19.

In the context of critical care, the evaluation of microcirculatory perfusion appears to be a diagnostic tool of major importance. Indeed, microcirculatory dysfunction is directly associated with increased organ failure and mortality in the ICU. In addition, many clinical situations such as sepsis or hemorrhagic shock may be responsible for a loss of hemodynamic coherence between macro and microcirculatory parameters. Thus, the correction of macrohemodynamic parameters (arterial pressure, cardiac output, plasma lactate, central venous oxygen saturation) may be associated with persistent microcirculatory hypoperfusion. It thus appears essential to develop systems for assessing the microcirculation in order to move towards resuscitation guided by microcirculatory objectives.

The aim of this study is to describe the sublingual microcirculation and to evaluate endothelial dysfunction in critically ill patient with Covid-19, and to determine whether there is a correlation between the severity of microcirculatory damage, endothelial dysfunction and clinically important outcomes in ICU. The data will serve to develop strategies for individualized management of high-risk patients screened with microcirculation evaluation.

• Study Type: Observational
• Enrollment (Anticipated): 40

Contacts and Locations

Study Locations

• France
  • Le Kremlin Bicêtre, France, 94270
    • Recruiting
    • Surgical Intensive Care Unit - Kremlin Bicêtre Hospital, APHP
    • Contact: Benjamin Bergis, MD; Phone Number: +33145212367; Email: benjamin.bergis@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Adult patients admitted to ICU for COVID-19

Description

Inclusion Criteria:

• Adult patient (≥ 18 ans)
• Affiliation to the French social security system
• Patient admitted to ICU within 72 hours before inclusion
• Patient presenting SARS-CoV-2 pneumonia diagnosed by CT scan or by COVID-19 PCR test

Exclusion Criteria:

• Lesions of the oral mucosa

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Covid-19 patients; Adult Covid-19 patients admitted to intensive care units

Other: Measurement of sublingual microcirculation; Sublingual microcirculation will be evaluated using a MicroScan (Microvision Medical, Amsterdam, the Netherlands) incident dark field imaging device. Perfusion measurements will be taken once a day during the first three days after inclusion (i.e. three measurement times). At each measurement time, five sequences of 20 secs will be recorded at five different sites. The video clips will be secondarily analyzed by a trained, blind investigator.; Other: Plasma sampling; Additional volume during blood draw to assess plasma levels of the following endothelial markers: syndecan-1, angiopoietin-2, vascular endothelial growth factor-A (VEGF-A), thrombomodulin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Microvascular flow index (MFI)	Change in a semi quantitative score evaluating the sublingual microcirculation using an incident dark field imaging device (Microscan, MicroVision Medical ) over the first days of ICU stay	At admission, on day 1 and day 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in perfused vessel density	Change in sublingual microcirculation over the first days of ICU stay as assessed by perfused vessel density evaluation	At admission, on day 1 and day 2
Change in plasma Syndecan-1 levels (in pg/ml)	Change in the levels of endothelium biomarker Syndecan-1 over the first days of ICU stay	At admission, on day 1 and day 2
Change in plasma Thrombomodulin levels (in arbitrary units/ml)	Change in the levels of endothelium biomarker Thrombomodulin over the first days of ICU stay	At admission, on day 1 and day 2
Change in plasma VEGF-A levels (in arbitrary units/ml)	Change in the levels of endothelium biomarker VEGF-A over the first days of ICU stay	At admission, on day 1 and day 2
Change in plasma Angiopoietin-2 levels (in ng/ml)	Change in the levels of endothelium biomarker Angiopoietin-2 over the first days of ICU stay	At admission, on day 1 and day 2
Change in cardiac output	Change in cardiac output (in ml/min) measured by transthoracic echocardiography over the first days in ICU stay	At admission, on day 1 and day 2
Blood D-dimer levels (in µg/l)	D-dimer level measurement to evaluate the prothrombotic condition	At admission
Neutrophil to Lymphocyte ratio	Neutrophil to Lymphocyte ratio measurement to evaluate the proinflammatory status	At admission
Blood C Reactive Protein levels (in mg/l)	C Reactive Protein levels measurement to evaluate the proinflammatory status	At admission
The ratio of arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)	PaO2/FiO2 ratio measurement to evaluate the severity of lung disease	At admission
The percentage of pulmonary lesions as assessed by computerized tomography (CT) scan	The percentage of pulmonary lesions as assessed by CT scan to evaluate the severity of lung disease at ICU admission	At admission
Mortality	Mortality rate in the ICU	Day 28
Invasive Mechanical ventilation	Number of days under invasive Mechanical ventilation in the ICU	Day 28
Length of stay in the ICU	Number of days of hospitalization in the ICU	Day 28
Acute kidney injury	Occurrence of acute kidney injury using KDIGO definition during the ICU stay	Day 28
Organ failure	Change in Sequential Organ Failure Assessment (SOFA) Score during the ICU stay (minimum value 0; maximum value 24; the higher score means a worst outcome).	Every day from Day 0 to Day 8, and at Day 28 after inclusion

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Study Director: Jacques Duranteau, MD, PhD, APHP, Kremlin Bicêtre Hospital

Study record dates

Study Major Dates

• Study Start (Actual): March 28, 2021
• Primary Completion (Anticipated): April 1, 2022
• Study Completion (Anticipated): October 1, 2022

Study Registration Dates

• First Submitted: March 26, 2021
• First Submitted That Met QC Criteria: March 26, 2021
• First Posted (Actual): March 29, 2021

Study Record Updates

• Last Update Posted (Actual): April 1, 2021
• Last Update Submitted That Met QC Criteria: March 31, 2021
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Keywords: SARS-CoV-2; Covid-19; Prospective Studies; Critical illness; Intensive Care Units; Hemodynamics; Microcirculation; Regional blood flow; Organ dysfunction scores; Covid-19 / Pathophysiology; Covid-19 / Virology; Microcirculation / Physiology; Microvessels / Physiopathology; Capillary permeability; SARS-CoV-2 / physiology; Biomarkers / Blood; Glycocalyx / metabolism; Glycocalyx / Pathology; Mouth mucosa / Blood supply; Syndecan-1 / Blood
• Additional Relevant MeSH Terms: Pathologic Processes; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; Disease Attributes; Severe Acute Respiratory Syndrome; COVID-19; Critical Illness
• Other Study ID Numbers: APHP210249; 2021-A00321-40 (Other Identifier: IDRCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No